This clinical trial is focused on studying Sjögren’s Syndrome, a condition that affects the body’s moisture-producing glands, leading to symptoms like dry mouth and eyes. The study will evaluate a treatment called Dazodalibep, also known by its code name HZN-4920. This treatment is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.